More recently, the therapeutic landscape has expanded substantially, with anti-CD38 therapy (daratumumab) demonstrating notable efficacy in refractory SLE [26] and CD19-directed CAR-T cell therapy achieving unprecedented drug-free remissions in multiply refractory patients [27,71,72]. This evidence concerns the gene CD19 and systemic lupus erythematosus.